Imaging Diagnosis and Treatment Selection for Brain Tumors in the Era of Molecular Therapeutics

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2022 Apr 19

PMID 35436952

Authors

Saivenkat Vagvala

Jeffrey P Guenette

Camilo Jaimes

Raymond Y Huang

Affiliations

Soon will be listed here.

Abstract

Currently, most CNS tumors require tissue sampling to discern their molecular/genomic landscape. However, growing research has shown the powerful role imaging can play in non-invasively and accurately detecting the molecular signature of these tumors. The overarching theme of this review article is to provide neuroradiologists and neurooncologists with a framework of several important molecular markers, their associated imaging features and the accuracy of those features. A particular emphasis is placed on those tumors and mutations that have specific or promising imaging correlates as well as their respective therapeutic potentials.

Citing Articles

The clinical potential of radiomics to predict hematoma expansion in spontaneous intracerebral hemorrhage: a narrative review.

Tenhoeve S, Findlay M, Cole K, Gautam D, Nelson J, Brown J Front Neurol. 2024; 15:1427555.

PMID: 39099779 PMC: 11297354. DOI: 10.3389/fneur.2024.1427555.

DSC-PWI presurgical differentiation of grade 4 astrocytoma and glioblastoma in young adults: rCBV percentile analysis across enhancing and non-enhancing regions.

Pons-Escoda A, Naval-Baudin P, Viveros M, Flores-Casaperalta S, Martinez-Zalacain I, Plans G Neuroradiology. 2024; 66(8):1267-1277.

PMID: 38834877 PMC: 11246293. DOI: 10.1007/s00234-024-03385-0.

Identification of Multiclass Pediatric Low-Grade Neuroepithelial Tumor Molecular Subtype with ADC MR Imaging and Machine Learning.

Soldatelli M, Namdar K, Tabori U, Hawkins C, Yeom K, Khalvati F AJNR Am J Neuroradiol. 2024; 45(6):753-760.

PMID: 38604736 PMC: 11288584. DOI: 10.3174/ajnr.A8199.

Identifying key factors for predicting O6-Methylguanine-DNA methyltransferase status in adult patients with diffuse glioma: a multimodal analysis of demographics, radiomics, and MRI by variable Vision Transformer.

Usuzaki T, Takahashi K, Inamori R, Morishita Y, Shizukuishi T, Takagi H Neuroradiology. 2024; 66(5):761-773.

PMID: 38472373 PMC: 11031474. DOI: 10.1007/s00234-024-03329-8.

Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles.

Pons-Escoda A, Garcia-Ruiz A, Naval-Baudin P, Martinez-Zalacain I, Castell J, Camins A Eur Radiol. 2024; 34(8):5320-5330.

PMID: 38282078 PMC: 11255054. DOI: 10.1007/s00330-024-10611-z.

References

Yamashita K, Hatae R, Hiwatashi A, Togao O, Kikuchi K, Momosaka D . Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma. Diagn Interv Imaging. 2019; 100(7-8):411-419. DOI: 10.1016/j.diii.2019.02.010. View

Arrillaga-Romany I, Odia Y, Prabhu V, Tarapore R, Merdinger K, Stogniew M . Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2019; 22(1):94-102. PMC: 7080220. DOI: 10.1093/neuonc/noz164. View

Barnholtz-Sloan J, Sloan A, Davis F, Vigneau F, Lai P, Sawaya R . Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22(14):2865-72. DOI: 10.1200/JCO.2004.12.149. View

Cho Y, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H . Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2010; 29(11):1424-30. PMC: 3082983. DOI: 10.1200/JCO.2010.28.5148. View

Zhao J, Huang Y, Song Y, Xie D, Hu M, Qiu H . Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis. Eur Radiol. 2020; 30(8):4664-4674. DOI: 10.1007/s00330-020-06717-9. View

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

Pfister S, Janzarik W, Remke M, Ernst A, Werft W, Becker N . BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008; 118(5):1739-49. PMC: 2289793. DOI: 10.1172/JCI33656. View

Lasocki A, Rosenthal M, Roberts-Thomson S, Neal A, Drummond K . Neuro-Oncology and Radiogenomics: Time to Integrate?. AJNR Am J Neuroradiol. 2020; 41(11):1982-1988. PMC: 7658841. DOI: 10.3174/ajnr.A6769. View

Caulo M, Panara V, Tortora D, Mattei P, Briganti C, Pravata E . Data-driven grading of brain gliomas: a multiparametric MR imaging study. Radiology. 2014; 272(2):494-503. DOI: 10.1148/radiol.14132040. View

10.

Tietze A, Choi C, Mickey B, Maher E, Ulhoi B, Sangill R . Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. J Neurosurg. 2017; 128(2):391-398. DOI: 10.3171/2016.10.JNS161793. View

11.

Mueller S, Jain P, Liang W, Kilburn L, Kline C, Gupta N . A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. Int J Cancer. 2019; 145(7):1889-1901. DOI: 10.1002/ijc.32258. View

12.

Jones D, Kocialkowski S, Liu L, Pearson D, Backlund L, Ichimura K . Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68(21):8673-7. PMC: 2577184. DOI: 10.1158/0008-5472.CAN-08-2097. View

13.

Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M . TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2014; 17(1):45-52. PMC: 4483052. DOI: 10.1093/neuonc/nou158. View

14.

Thon N, Kunz M, Lemke L, Jansen N, Eigenbrod S, Kreth S . Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. Int J Cancer. 2014; 136(9):2132-45. DOI: 10.1002/ijc.29259. View

15.

Brastianos P, Carter S, Santagata S, Cahill D, Taylor-Weiner A, Jones R . Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015; 5(11):1164-1177. PMC: 4916970. DOI: 10.1158/2159-8290.CD-15-0369. View

16.

Zapotocky M, Mata-Mbemba D, Sumerauer D, Liby P, Lassaletta A, Zamecnik J . Differential patterns of metastatic dissemination across medulloblastoma subgroups. J Neurosurg Pediatr. 2017; 21(2):145-152. DOI: 10.3171/2017.8.PEDS17264. View

17.

Pan C, Liu J, Tang J, Chen X, Chen F, Wu Y . A machine learning-based prediction model of H3K27M mutations in brainstem gliomas using conventional MRI and clinical features. Radiother Oncol. 2018; 130:172-179. DOI: 10.1016/j.radonc.2018.07.011. View

18.

deSouza R, Jones B, Lowis S, Kurian K . Pediatric medulloblastoma - update on molecular classification driving targeted therapies. Front Oncol. 2014; 4:176. PMC: 4105823. DOI: 10.3389/fonc.2014.00176. View

19.

Patel S, Poisson L, Brat D, Zhou Y, Cooper L, Snuderl M . T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clin Cancer Res. 2017; 23(20):6078-6085. DOI: 10.1158/1078-0432.CCR-17-0560. View

20.

Aquilanti E, Miller J, Santagata S, Cahill D, Brastianos P . Updates in prognostic markers for gliomas. Neuro Oncol. 2018; 20(suppl_7):vii17-vii26. PMC: 6225747. DOI: 10.1093/neuonc/noy158. View